David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Websites

Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

American Cancer Society: Physician Research Award, 1996
– 2001
Sloan-Kettering Institute: Clinical Scholar Award, 1996
American Cancer Society: Clinical Oncology Fellowship Award, 1994
HealthNetwork Foundation: Excellence Award, 2008
Geoffrey Beene Foundation: Rock Stars of Science™, 2009
Biotech Humanitarian Award: Selected Judge, 2009
USC Association of Trojan Leagues: Outstanding Service Award, 2013
American College of Physicians: Fellow, 2016
Ellis Island Medal of Honor: Medalist, 2017

Research Funding

(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
UCLA SPORE in Prostate Cancer
NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Media

Sixty-five simple rules to maintain good health (1/8/2014)
Agus relishes his role as a health care rebel (10/11/2012)
Agus' book focuses on new view of health (1/17/2012)
USC Welcomes Oncologist David Agus (06/30/2009)

Publications

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37.. View in PubMed
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46.. View in PubMed
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55.. View in PubMed
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93.. View in PubMed
Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11720-4.. View in PubMed
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001 Sep; 7(9):2643-7.. View in PubMed
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr; 7(4):962-70.. View in PubMed
A potential role for activated HER-2 in prostate cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):76-83.. View in PubMed
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63.. View in PubMed
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000 Nov 01; 60(21):6134-41.. View in PubMed